<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Biologic agents for add-on therapy for treatment of adults with CRSwNP</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Biologic agents for add-on therapy for treatment of adults with CRSwNP</h1>
<div class="graphic"><div class="figure"><div class="ttl">Biologic agents for add-on therapy for treatment of adults with CRSwNP</div><div class="cntnt"><table cellspacing="0"><colgroup width="12%"></colgroup><colgroup span="2" width="16%"></colgroup><colgroup span="2" width="12%"></colgroup><colgroup span="2" width="16%"></colgroup> <tbody> <tr> <td class="subtitle1">Agent and target</td> <td class="subtitle1">CRSwNP study primary outcomes</td> <td class="subtitle1">Indications in addition to CRSwNP</td> <td class="subtitle1">CRSwNP dose and route</td> <td class="subtitle1">Administration options</td> <td class="subtitle1">Most common adverse effects in CRSwNP</td> <td class="subtitle1">Other important adverse events reported with drug</td> </tr> <tr> <td><strong>Dupilumab, anti-IL-4R alpha</strong></td> <td><strong>NPS:</strong> <ul class="decimal_heading"> <li>SINUS 24: 2.06 point reduction (95% CI –2.43 to –1.69)</li> <li>SINUS 52: 1.80 point reduction (95% CI –2.10 to –1.51)</li> </ul> <p class="extra_spacing_top"><strong>NCS:</strong></p> <ul class="decimal_heading"> <li>SINUS 24: 0.89 point reduction (95% CI –1.07 to –0.71)</li> <li>SINUS 52: 0.87 point reduction (95% CI –1.03 to –0.71)<sup>[1]</sup></li> </ul> </td> <td> <ul> <li>Atopic dermatitis</li> <li>Moderate-to-severe eosinophilic asthma</li> <li>Eosinophilic esophagitis</li> <li>Prurigo nodularis</li> </ul> </td> <td>300 mg SUBQ every 14 days</td> <td>Self-administration</td> <td> <ul> <li>Injection-site reactions</li> <li>Eosinophilia</li> <li>Insomnia</li> <li>Toothache</li> <li>Gastritis</li> <li>Arthralgia</li> <li>Conjunctivitis<sup>[2]</sup></li> </ul> </td> <td> <ul> <li>Keratitis</li> <li>Oral and other herpes simplex viral infections</li> </ul> </td> </tr> <tr class="highlight_gray_text"> <td><strong>Omalizumab, anti-IgE</strong></td> <td><strong>NPS:</strong> <ul class="decimal_heading"> <li>POLYP 1: 1.14 point reduction (95% CI –1.59 to –0.69)</li> <li>POLYP 2: 0.59 point reduction (95% CI –1.05 to –0.12)</li> </ul> <p class="extra_spacing_top"><strong>NCS:</strong></p> <ul class="decimal_heading"> <li>POLYP 1: 0.55 point reduction (95% CI –0.84 to –0.25)</li> <li>POLYP 2: 0.50 point reduction (95% CI –0.80 to –0.19)<sup>[3]</sup></li> </ul> </td> <td> <ul> <li>Allergic asthma</li> <li>Chronic spontaneous urticaria</li> </ul> </td> <td>75 mg to 600 mg SUBQ every 2 or 4 weeks based on weight and serum IgE level</td> <td>Office administration or self-administration after 3 observed doses in the office in patients without history of anaphylaxis</td> <td> <ul> <li>Headache</li> <li>Injection-site reactions</li> <li>Arthralgia</li> <li>Upper abdominal pain</li> <li>Dizziness<sup>[4]</sup></li> </ul> </td> <td> <ul> <li>Anaphylaxis, immediate or delayed</li> <li>Thromboembolic disease</li> </ul> </td> </tr> <tr> <td><strong>Mepolizumab, anti-IL-5</strong></td> <td><strong>NPS:</strong> <ul class="decimal_heading"> <li>0.73 point reduction (95% CI –1.11 to –0.34)</li> </ul> <p class="extra_spacing_top"><strong>Nasal obstruction VAS:</strong></p> <ul class="decimal_heading"> <li>3.14 point reduction (95% CI –4.09 to –2.18)<sup>[5]</sup></li> </ul> </td> <td> <ul> <li>Severe asthma with eosinophilic phenotype</li> <li>Hypereosinophilic syndrome</li> <li>Eosinophilic granulomatosis with polyangiitis</li> </ul> </td> <td>100 mg SUBQ every 28 days</td> <td>Office administration or self-administration</td> <td> <ul> <li>Oropharyngeal pain</li> <li>Arthralgia<sup>[6]</sup></li> </ul> </td> <td> <ul> <li>Headache</li> <li>Anaphylaxis</li> <li>Herpes zoster infections; administration of zoster vaccine is suggested prior to start</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd"><ul>
<li>Endoscopic NPS measurement – Scale of 0 (no polyps) to 8 (complete obstruction of nasal cavity bilaterally).</li>
<li>NCS – Scale of 0 (no congestion) to 3 (severe congestion).</li>
<li>Nasal obstruction VAS – Scale of 0 (no obstruction) to 10 (severe obstruction).</li>
</ul></div><div class="graphic_footnotes">CRSwNP: chronic rhinosinusitis with nasal polyposis; IL-4R: interleukin 4 receptor; NPS: nasal polyp score; SINUS 24 and 52: Controlled Clinical Studies of Dupilumab in Patients with Bilateral Nasal Polyp; NCS: nasal congestion score; SUBQ: subcutaneous; IgE: immunoglobulin E; POLYP 1 and 2: Participants with Chronic Rhinosinusitis with Nasal Polyps trials 1 and 2; IL-5: interleukin 5; VAS: visual analog scale.</div><div class="graphic_reference">References:
<ol>
<li>Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): Results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet 2019; 394:1638.</li>
<li>Dupilumab injection. United States prescribing information. Revised October, 2022. US National Library of Medicine. (Available online at <a href="https://www.dailymed.nlm.nih.gov/dailymed/index.cfm" target="_blank">www.dailymed.nlm.nih.gov/dailymed/index.cfm</a>, accessed January 23, 2023.)</li>
<li>Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol 2020; 146:595.</li>
<li>Omalizumab injection. United States prescribing information. Revised July 2021. US National Library of Medicine. (Available online at <a href="https://www.dailymed.nlm.nih.gov/dailymed/index.cfm" target="_blank">www.dailymed.nlm.nih.gov/dailymed/index.cfm</a>, accessed January 23, 2023.)</li>
<li>Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med 2021; 9:1141.</li>
<li>Mepolizumab injection. United States prescribing information. Revised January, 2022. US National Library of Medicine. (Available online at <a href="https://www.dailymed.nlm.nih.gov/dailymed/index.cfm" target="_blank">www.dailymed.nlm.nih.gov/dailymed/index.cfm</a>, accessed January 23, 2023.)</li>
</ol></div><div id="graphicVersion">Graphic 140812 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
